A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Meningitis still affects more than 2.5 million people globally each year
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The product is expected to be launched by Q4 FY23.
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
It is a novel oral NLRP3 inflammasome inhibitor
Subscribe To Our Newsletter & Stay Updated
